PDF(Pubmed)
Abstract：
UNASSIGNED: Poly (ADP-Ribose) Polymerase (PARP) inhibitors represent a novel class of drugs that hinder DNA repair mechanisms in tumor cells, leading to cell death. This systematic review aims to evaluate the effectiveness, safety, and potential adverse effects of PARP inhibitors (PARPi) in the management of patients with advanced lung cancer.
UNASSIGNED: We conducted a comprehensive search for relevant studies in PubMed, Embase, Cochrane, and ClinicalTrials.gov. We extracted primary and secondary outcome measures, including progression-free survival (PFS), overall survival (OS), and adverse events (AEs), from the identified literature for subsequent meta-analysis and systematic review.
UNASSIGNED: This study encompassed twelve randomized controlled trials, involving 3,132 patients with advanced lung cancer. In comparison to non-PARPi treatments, the administration of PARPi significantly extended OS (hazard ratio (HR) = 0.90, 95% CI = 0.83-0.97, p = 0.006). However, the difference in PFS did not reach statistical significance.
UNASSIGNED: In summary, therapies incorporating PARPi provide a degree of benefit by extending OS in patients with advanced lung cancer. Nonetheless, further trials are necessary to furnish additional evidence regarding the efficacy and safety of PARPi in the treatment of lung cancer.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier number: CRD42023424673.
UNASSIGNED: We conducted a comprehensive search for relevant studies in PubMed, Embase, Cochrane, and ClinicalTrials.gov. We extracted primary and secondary outcome measures, including progression-free survival (PFS), overall survival (OS), and adverse events (AEs), from the identified literature for subsequent meta-analysis and systematic review.
UNASSIGNED: This study encompassed twelve randomized controlled trials, involving 3,132 patients with advanced lung cancer. In comparison to non-PARPi treatments, the administration of PARPi significantly extended OS (hazard ratio (HR) = 0.90, 95% CI = 0.83-0.97, p = 0.006). However, the difference in PFS did not reach statistical significance.
UNASSIGNED: In summary, therapies incorporating PARPi provide a degree of benefit by extending OS in patients with advanced lung cancer. Nonetheless, further trials are necessary to furnish additional evidence regarding the efficacy and safety of PARPi in the treatment of lung cancer.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier number: CRD42023424673.
摘要：
■聚（ADP-核糖）聚合酶（PARP）抑制剂代表了一类新型的药物，可以阻碍肿瘤细胞中的DNA修复机制，导致细胞死亡。本系统综述旨在评估有效性，安全,以及PARP抑制剂（PARPi）在晚期肺癌患者治疗中的潜在不良反应。
■我们对PubMed的相关研究进行了全面搜索，Embase,科克伦,和ClinicalTrials.gov.我们提取了主要和次要结果指标，包括无进展生存期（PFS），总生存期（OS），和不良事件（AE），从确定的文献中进行后续的荟萃分析和系统评价。
■这项研究包括12项随机对照试验，涉及3132例晚期肺癌患者.与非PARPi治疗相比，PARPi的给药显著延长了OS(风险比(HR)=0.90,95%CI=0.83-0.97,p=0.006).然而,PFS差异无统计学意义。
■总之，纳入PARPi的治疗可通过延长晚期肺癌患者的OS来提供一定程度的获益.尽管如此，需要进一步的试验来提供有关PARPi治疗肺癌的有效性和安全性的更多证据.
系统审查注册：https://www。crd.约克。AC.英国/PROSPERO/,标识号:CRD42023424673。
■我们对PubMed的相关研究进行了全面搜索，Embase,科克伦,和ClinicalTrials.gov.我们提取了主要和次要结果指标，包括无进展生存期（PFS），总生存期（OS），和不良事件（AE），从确定的文献中进行后续的荟萃分析和系统评价。
■这项研究包括12项随机对照试验，涉及3132例晚期肺癌患者.与非PARPi治疗相比，PARPi的给药显著延长了OS(风险比(HR)=0.90,95%CI=0.83-0.97,p=0.006).然而,PFS差异无统计学意义。
■总之，纳入PARPi的治疗可通过延长晚期肺癌患者的OS来提供一定程度的获益.尽管如此，需要进一步的试验来提供有关PARPi治疗肺癌的有效性和安全性的更多证据.
系统审查注册：https://www。crd.约克。AC.英国/PROSPERO/,标识号:CRD42023424673。
